Iradimed CEO Roger Susi Indirectly Sells 7,500 Shares of Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IRMD?
Source: Fool
- Transaction Overview: Roger E. Susi, CEO of Iradimed Corporation, indirectly sold 7,500 shares of common stock on April 20 and 21, 2026, for a total value of $694,125, based on a weighted average purchase price of $92.55, indicating a systematic disposition strategy.
- Shareholding Structure: Post-transaction, Susi holds no direct shares, with all shares held indirectly through designated trust entities, underscoring a reliance on indirect ownership for liquidity, and the sale impacted only 0.17% of his total holdings.
- Market Performance Context: As of the transaction date, Iradimed shares appreciated 68.79% over the past year, reflecting strong company performance in the medical device market, with 2025 sales rising 14% year-over-year to $83.81 million and net income increasing to $22.48 million.
- Investor Implications: The sale was executed under a Rule 10b5-1 trading plan adopted in November 2025 to avoid insider trading accusations, with Susi retaining over 4 million indirectly-held shares, demonstrating continued confidence in the company despite the stock reaching a 52-week high of $107.90.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRMD
Wall Street analysts forecast IRMD stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 89.080
Low
98.00
Averages
99.00
High
100.00
Current: 89.080
Low
98.00
Averages
99.00
High
100.00
About IRMD
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iradimed to Release Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: Iradimed Corporation will announce its first quarter financial results for 2026 before the market opens on May 1, 2026, reflecting its ongoing advancements in MRI-compatible medical devices.
- Conference Call Details: Management will host a conference call on the same day at 11:00 a.m. Eastern Time to discuss the financial results and answer questions, enhancing investor communication and transparency.
- Innovative Product Introduction: Iradimed's MRidium® IV infusion pump system is the only known non-magnetic infusion pump specifically designed for MRI procedures, ensuring safe and reliable delivery of anesthesia and other IV fluids during scans.
- Monitoring System Advantages: The Iradimed 3880 monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of critically ill patients' vital signs during MRI procedures, thereby enhancing patient safety.
See More
Iradimed CEO Roger Susi Indirectly Sells 7,500 Shares of Stock
- Transaction Overview: Roger E. Susi, CEO of Iradimed Corporation, indirectly sold 7,500 shares of common stock on April 20 and 21, 2026, for a total value of $694,125, based on a weighted average purchase price of $92.55, indicating a systematic disposition strategy.
- Shareholding Structure: Post-transaction, Susi holds no direct shares, with all shares held indirectly through designated trust entities, underscoring a reliance on indirect ownership for liquidity, and the sale impacted only 0.17% of his total holdings.
- Market Performance Context: As of the transaction date, Iradimed shares appreciated 68.79% over the past year, reflecting strong company performance in the medical device market, with 2025 sales rising 14% year-over-year to $83.81 million and net income increasing to $22.48 million.
- Investor Implications: The sale was executed under a Rule 10b5-1 trading plan adopted in November 2025 to avoid insider trading accusations, with Susi retaining over 4 million indirectly-held shares, demonstrating continued confidence in the company despite the stock reaching a 52-week high of $107.90.
See More
Iradimed to Participate in 25th Annual Needham Virtual Healthcare Conference
- Conference Participation: Iradimed Corporation will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, where CFO Jack Glenn will hold one-on-one meetings with investors to enhance engagement and raise company visibility.
- Product Innovation: The MRidium® MRI-compatible IV infusion pump system developed by Iradimed is the only known non-magnetic infusion pump specifically designed for MRI procedures, enabling safe and reliable delivery of anesthesia and other IV fluids during scans, significantly reducing risks associated with traditional pumps.
- Monitoring System Advantages: The Iradimed 3880 MRI-compatible patient vital signs monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of patient vital signs during MRI scans, thereby enhancing safety for critically ill patients and minimizing their time away from critical care units.
- Technical Features: This monitoring system includes features such as wireless ECG, wireless SpO2, non-magnetic respiratory CO2, and blood pressure monitoring, all designed for ease of use, effectively communicating patient vital signs to clinicians and improving clinical communication efficiency.
See More
Iradimed Corporation to Participate in 38th Annual Roth Conference
- Conference Participation: Iradimed Corporation will participate in the 38th Annual Roth Conference from March 22 to 24, 2026, at the Ritz-Carlton in Laguna Niguel, CA, where CEO Roger Susi and CFO Jack Glenn will hold one-on-one meetings with investors to strengthen relationships and showcase the company's innovative capabilities.
- Product Innovation: Iradimed is the only provider of a non-magnetic intravenous infusion pump system specifically designed for MRI procedures, enabling safe and reliable delivery of anesthesia and other IV fluids, significantly reducing common risks associated with MRI operations.
- Monitoring System Advantages: The Iradimed 3880 MRI-compatible patient vital signs monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of patient vital signs during MRI scans, thereby enhancing the safety of critically ill patients.
- Technical Features: This monitoring system includes features such as wireless ECG, wireless SpO2, and non-magnetic respiratory CO2, with a compact and lightweight design that facilitates use during patient transfers, ensuring that critically ill patients remain in critical care units during MRI scans.
See More
IRadimed (IRMD.US) Officer Plans to Sell $9.87 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Roger E. Susi intends to sell 100,000 shares of Iradimed's common stock on March 6, with a total market value of approximately $9.87 million.
Reduction in Shareholding: Since December 8, 2025, Roger E. Susi has reduced his shareholding in Iradimed by 40,000 shares, valued at approximately $3.92 million.
See More
Nine Ten Capital Management Sells IRadimed Shares Worth $29.42 Million
- Share Reduction Details: Nine Ten Capital Management sold 342,907 shares of IRadimed in Q4 2026, with an estimated trade value of $29.42 million, reflecting the impact of share price changes and the sale on its investment portfolio.
- Portfolio Adjustment: Following the sale, IRadimed now represents 13.2% of Nine Ten's 13F reportable assets, indicating a cautious approach to managing concentration risk within the fund's holdings.
- Strong Company Performance: IRadimed achieved its 18th consecutive quarter of record revenue in 2025, with Q4 sales reaching $22.7 million, a 17% year-over-year increase, showcasing its robust position in the MRI-compatible medical device market.
- Future Outlook: The company anticipates revenue of up to $96 million in 2026, with the broader rollout of the new 3870 MRI-compatible infusion pump expected to drive further growth, suggesting that long-term investors should focus on fundamentals despite the recent share reduction.
See More
Iradimed to Release Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: Iradimed Corporation will announce its first quarter financial results for 2026 before the market opens on May 1, 2026, reflecting its ongoing advancements in MRI-compatible medical devices.
- Conference Call Details: Management will host a conference call on the same day at 11:00 a.m. Eastern Time to discuss the financial results and answer questions, enhancing investor communication and transparency.
- Innovative Product Introduction: Iradimed's MRidium® IV infusion pump system is the only known non-magnetic infusion pump specifically designed for MRI procedures, ensuring safe and reliable delivery of anesthesia and other IV fluids during scans.
- Monitoring System Advantages: The Iradimed 3880 monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of critically ill patients' vital signs during MRI procedures, thereby enhancing patient safety.
See More
Iradimed CEO Roger Susi Indirectly Sells 7,500 Shares of Stock
- Transaction Overview: Roger E. Susi, CEO of Iradimed Corporation, indirectly sold 7,500 shares of common stock on April 20 and 21, 2026, for a total value of $694,125, based on a weighted average purchase price of $92.55, indicating a systematic disposition strategy.
- Shareholding Structure: Post-transaction, Susi holds no direct shares, with all shares held indirectly through designated trust entities, underscoring a reliance on indirect ownership for liquidity, and the sale impacted only 0.17% of his total holdings.
- Market Performance Context: As of the transaction date, Iradimed shares appreciated 68.79% over the past year, reflecting strong company performance in the medical device market, with 2025 sales rising 14% year-over-year to $83.81 million and net income increasing to $22.48 million.
- Investor Implications: The sale was executed under a Rule 10b5-1 trading plan adopted in November 2025 to avoid insider trading accusations, with Susi retaining over 4 million indirectly-held shares, demonstrating continued confidence in the company despite the stock reaching a 52-week high of $107.90.
See More
Iradimed to Participate in 25th Annual Needham Virtual Healthcare Conference
- Conference Participation: Iradimed Corporation will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, where CFO Jack Glenn will hold one-on-one meetings with investors to enhance engagement and raise company visibility.
- Product Innovation: The MRidium® MRI-compatible IV infusion pump system developed by Iradimed is the only known non-magnetic infusion pump specifically designed for MRI procedures, enabling safe and reliable delivery of anesthesia and other IV fluids during scans, significantly reducing risks associated with traditional pumps.
- Monitoring System Advantages: The Iradimed 3880 MRI-compatible patient vital signs monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of patient vital signs during MRI scans, thereby enhancing safety for critically ill patients and minimizing their time away from critical care units.
- Technical Features: This monitoring system includes features such as wireless ECG, wireless SpO2, non-magnetic respiratory CO2, and blood pressure monitoring, all designed for ease of use, effectively communicating patient vital signs to clinicians and improving clinical communication efficiency.
See More
Iradimed Corporation to Participate in 38th Annual Roth Conference
- Conference Participation: Iradimed Corporation will participate in the 38th Annual Roth Conference from March 22 to 24, 2026, at the Ritz-Carlton in Laguna Niguel, CA, where CEO Roger Susi and CFO Jack Glenn will hold one-on-one meetings with investors to strengthen relationships and showcase the company's innovative capabilities.
- Product Innovation: Iradimed is the only provider of a non-magnetic intravenous infusion pump system specifically designed for MRI procedures, enabling safe and reliable delivery of anesthesia and other IV fluids, significantly reducing common risks associated with MRI operations.
- Monitoring System Advantages: The Iradimed 3880 MRI-compatible patient vital signs monitoring system operates reliably in magnetic fields up to 30,000 gauss, ensuring continuous monitoring of patient vital signs during MRI scans, thereby enhancing the safety of critically ill patients.
- Technical Features: This monitoring system includes features such as wireless ECG, wireless SpO2, and non-magnetic respiratory CO2, with a compact and lightweight design that facilitates use during patient transfers, ensuring that critically ill patients remain in critical care units during MRI scans.
See More
IRadimed (IRMD.US) Officer Plans to Sell $9.87 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Roger E. Susi intends to sell 100,000 shares of Iradimed's common stock on March 6, with a total market value of approximately $9.87 million.
Reduction in Shareholding: Since December 8, 2025, Roger E. Susi has reduced his shareholding in Iradimed by 40,000 shares, valued at approximately $3.92 million.
See More
Nine Ten Capital Management Sells IRadimed Shares Worth $29.42 Million
- Share Reduction Details: Nine Ten Capital Management sold 342,907 shares of IRadimed in Q4 2026, with an estimated trade value of $29.42 million, reflecting the impact of share price changes and the sale on its investment portfolio.
- Portfolio Adjustment: Following the sale, IRadimed now represents 13.2% of Nine Ten's 13F reportable assets, indicating a cautious approach to managing concentration risk within the fund's holdings.
- Strong Company Performance: IRadimed achieved its 18th consecutive quarter of record revenue in 2025, with Q4 sales reaching $22.7 million, a 17% year-over-year increase, showcasing its robust position in the MRI-compatible medical device market.
- Future Outlook: The company anticipates revenue of up to $96 million in 2026, with the broader rollout of the new 3870 MRI-compatible infusion pump expected to drive further growth, suggesting that long-term investors should focus on fundamentals despite the recent share reduction.
See More
